Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Global Value Dossier

- PMLiVE

NICE set to reject Kyowa Kirin’s Crysvita for XLH

Committee says the rare disease therapy isn’t value for money

- PMLiVE

More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease

Cell and gene therapy specialist Bluebird going head-to-head with partner Celgene

- PMLiVE

UK firm Nightstar bags FDA fast-track status for gene therapy

Its choroideremia disease candidate gets RMAT designation

- PMLiVE

British Business Bank sets up £2.5bn fund for ‘unicorn’ firms

UK government says the private sector will bring in another £5bn in investments

- PMLiVE

Anthill Agency launch digital-focused academy

Partners with Actando’s PharmAcademy to boost pharma’s digital skills

- PMLiVE

Eisai to tackle dementia in new US research facility

Aims to introduce a new compound into the clinic by 2020

- PMLiVE

AMICULUM launch specialist agency

Seques will be led by Jenny Szkolar and Patricia Jones

- PMLiVE

Sage surges after depression drug gets rapid path to approval

Will be able to file a marketing application based on its phase II trial

Weekly comms appointments

Publicis Resolute, Road and W2O all add to their teams

- PMLiVE

UK, Germany back routine use of J&J’s Tremfya

The IL-23 inhibitor is currently being assessed in other EU countries

- PMLiVE

Revenue down the back of the beanbag

How to engage with employees to create a sophisticated strategy

Australian Flu and the dilemma of naming diseases

During the winter of 2017-2018 not a day passed when the Australian flu was not mentioned by the UK press. The British media turned talking about Australian flu into an...

Say Communications

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links